104 related articles for article (PubMed ID: 30827261)
1. Synergistic Effect of Novel EGFR Inhibitor AZD8931 and p38α siRNA in Lung Adenocarcinoma Cancer Cells.
Zarredar H; Farajnia S; Ansarin K; Baradaran B; Aria M; Asadi M
Anticancer Agents Med Chem; 2019; 19(5):638-644. PubMed ID: 30827261
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
3. Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor.
Zarredar H; Pashapour S; Farajnia S; Ansarin K; Baradaran B; Ahmadzadeh V; Safari F
J Cell Biochem; 2019 Jun; 120(6):10670-10677. PubMed ID: 30656741
[TBL] [Abstract][Full Text] [Related]
4. [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Zhou Y; Zhang S; Li K; Li QW; Zhou FZ; Li ZY; Ma H; Dong XR; Liu L; Wu G; Meng R
Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):100-4. PubMed ID: 26899328
[TBL] [Abstract][Full Text] [Related]
5. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
Ko JC; Chiu HC; Wo TY; Huang YJ; Tseng SC; Huang YC; Chen HJ; Syu JJ; Chen CY; Jian YT; Jian YJ; Lin YW
Lung Cancer; 2013 Dec; 82(3):397-406. PubMed ID: 24138903
[TBL] [Abstract][Full Text] [Related]
7. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
[TBL] [Abstract][Full Text] [Related]
9. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
[TBL] [Abstract][Full Text] [Related]
10. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
11. [Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines].
Zhao YM; Su B; Yang XJ; Shi JY; Tang L; Zhang J; Li JY; Chen J
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):103-8. PubMed ID: 23714663
[TBL] [Abstract][Full Text] [Related]
12. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
13. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Bircan HA; Gurbuz N; Pataer A; Caner A; Kahraman N; Bayraktar E; Bayraktar R; Erdogan MA; Kabil N; Ozpolat B
Lung Cancer; 2018 Oct; 124():31-39. PubMed ID: 30268477
[TBL] [Abstract][Full Text] [Related]
14. Quinalizarin, a specific CK2 inhibitor, reduces cell viability and suppresses migration and accelerates apoptosis in different human lung cancer cell lines.
Zhou Y; Li K; Zhang S; Li Q; Li Z; Zhou F; Dong X; Liu L; Wu G; Meng R
Indian J Cancer; 2015 Dec; 52 Suppl 2():e119-24. PubMed ID: 26728669
[TBL] [Abstract][Full Text] [Related]
15. PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
Zhao XM; Pan SY; Huang QL; Lu YN; Wu XH; Chang JH; Liu ZB; Cai XW; Liu Q; Wang JL; Fu XL
Oncotarget; 2016 Aug; 7(31):49384-49396. PubMed ID: 27283902
[TBL] [Abstract][Full Text] [Related]
16. Vitamin A (retinol) downregulates the receptor for advanced glycation endproducts (RAGE) by oxidant-dependent activation of p38 MAPK and NF-kB in human lung cancer A549 cells.
de Bittencourt Pasquali MA; Gelain DP; Zeidán-Chuliá F; Pires AS; Gasparotto J; Terra SR; Moreira JC
Cell Signal; 2013 Apr; 25(4):939-54. PubMed ID: 23333461
[TBL] [Abstract][Full Text] [Related]
17. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
18. Effects of TGF-β signaling blockade on human A549 lung adenocarcinoma cell lines.
Xu CC; Wu LM; Sun W; Zhang N; Chen WS; Fu XN
Mol Med Rep; 2011; 4(5):1007-15. PubMed ID: 21725601
[TBL] [Abstract][Full Text] [Related]
19. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
20. Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells.
Ikari A; Sato T; Watanabe R; Yamazaki Y; Sugatani J
Biochim Biophys Acta; 2012 Jun; 1823(6):1110-8. PubMed ID: 22546605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
